Eurofarma Ventures
Overview
Eurofarma Ventures is the corporate venture capital arm of Eurofarma Laboratórios, focusing on early-stage investments in biotech companies in the US and Europe. The fund targets therapeutics and platform companies, with a focus on precision medicine, gene editing, new therapeutic targets, and artificial intelligence applied to molecule discovery.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| PsiThera | Dec 2025 | Series A | Co-investor |
| Abcuro | Aug 2026 | Series D | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Eurofarma Ventures based?
Eurofarma Ventures is headquartered in São Paulo, Brazil.
When was Eurofarma Ventures founded?
Eurofarma Ventures was founded in 2023.
How many portfolio companies does Eurofarma Ventures have?
Eurofarma Ventures has 4 portfolio companies in Caplight's dataset.
What are some companies in Eurofarma Ventures's portfolio?
Portfolio companies visible on Caplight include PsiThera, Abcuro.
What was Eurofarma Ventures's most recent investment shown here?
Eurofarma Ventures's most recent investment in this portfolio sample was in Abcuro in 2026.
What sectors does Eurofarma Ventures focus on?
Eurofarma Ventures focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Enterprise Software.
What company stages does Eurofarma Ventures focus on?
Eurofarma Ventures typically invests at the Early stage.
What is Eurofarma Ventures's AUM?
Eurofarma Ventures's assets under management are estimated between $100.0M and $100.0M.